• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Pharmacokinetics of cyclophosphamide in man.环磷酰胺在人体中的药代动力学。
Br J Pharmacol. 1971 Nov;43(3):677-80. doi: 10.1111/j.1476-5381.1971.tb07199.x.
2
Phenobarbital effects on cyclophosphamide pharmacokinetics in man.苯巴比妥对人体中环磷酰胺药代动力学的影响。
Cancer Res. 1972 Dec;32(12):2761-4.
3
Simultaneous tubular excretion and reabsorption of pindolol in man.人体中吲哚洛尔的同时肾小管排泄与重吸收
Eur J Clin Pharmacol. 1981;21(1):65-72. doi: 10.1007/BF00609590.
4
The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects.环磷酰胺在人体内的生物转化：正常受试者的变异分析。
Acta Pharmacol Toxicol (Copenh). 1974 Aug;35(2):98-106. doi: 10.1111/j.1600-0773.1974.tb00729.x.
5
Studies on the human pharmacokinetics of isophosphamide (NSC-109724).异环磷酰胺（NSC-109724）的人体药代动力学研究。
Cancer Treat Rep. 1976 Apr;60(4):451-8.
6
PLasma half-life and urinary excretion of cyclophosphamide in children.儿童中环磷酰胺的血浆半衰期及尿排泄情况。
Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1061-6.
7
Effect of phenobarbital and SKF 525A on the toxicity, elimination and metabolism of cyclophosphamide in newborn mice.苯巴比妥和SKF 525A对新生小鼠中环磷酰胺毒性、消除及代谢的影响。
J Pharmacol Exp Ther. 1973 Mar;184(3):749-56.
8
Clinical pharmacology of cyclophosphamide.环磷酰胺的临床药理学
Cancer Res. 1973 Feb;33(2):226-33.
9
Clearance and recovery calculations in hemodialysis: application to plasma, red blood cells, and dialysate measurements for cyclophosphamide.血液透析中的清除率和回收率计算：应用于环磷酰胺的血浆、红细胞及透析液测量
Clin Pharmacol Ther. 1981 Mar;29(3):365-72. doi: 10.1038/clpt.1981.50.
10
The comparative pharmacology of cyclophosphamide and ifosfamide.环磷酰胺与异环磷酰胺的比较药理学
Semin Oncol. 1982 Dec;9(4 Suppl 1):2-7.

引用本文的文献

1
Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions.多西他赛、环磷酰胺和表柔比星：群体药代动力学模型在药物相互作用中的应用，以获得新的认识。
J Pharmacokinet Pharmacodyn. 2024 Aug;51(4):367-384. doi: 10.1007/s10928-024-09912-z. Epub 2024 Mar 30.
2
Symptomatic hyponatremia induced by low-dose cyclophosphamide in patient with systemic lupus erythematosus: A case report.低剂量环磷酰胺诱发系统性红斑狼疮患者出现症状性低钠血症：一例报告
Medicine (Baltimore). 2020 Nov 25;99(48):e22498. doi: 10.1097/MD.0000000000022498.
3
Water intoxication following low-dose intravenous cyclophosphamide.低剂量静脉注射环磷酰胺后的水中毒
Electrolyte Blood Press. 2007 Jun;5(1):50-4. doi: 10.5049/EBP.2007.5.1.50. Epub 2007 Jun 30.
4
Clinical pharmacokinetics of cyclophosphamide.环磷酰胺的临床药代动力学
Clin Pharmacokinet. 2005;44(11):1135-64. doi: 10.2165/00003088-200544110-00003.
5
Preclinical pharmacokinetics and stability of isophosphoramide mustard.异环磷酰胺氮芥的临床前药代动力学与稳定性
Cancer Chemother Pharmacol. 1994;33(5):391-8. doi: 10.1007/BF00686268.
6
The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy.采用气相色谱法研究接受环磷酰胺治疗的患者中环磷酰胺、磷酰胺氮芥和去甲氮芥的药代动力学。
Br J Clin Pharmacol. 1980 Oct;10(4):327-35. doi: 10.1111/j.1365-2125.1980.tb01768.x.
7
[Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].人体内活化环磷酰胺及其失活产物的血药浓度和尿排泄情况（作者译）
J Cancer Res Clin Oncol. 1980 Jan;96(1):79-92. doi: 10.1007/BF00412899.
8
Cyclophosphamide and dimethylsulfoxide in the treatment of squamous carcinoma of the lung. Therapeutic efficacy, toxicity, and pharmacokinetics.环磷酰胺与二甲基亚砜治疗肺鳞状细胞癌。治疗效果、毒性及药代动力学。
Cancer Chemother Pharmacol. 1981;6(2):117-20. doi: 10.1007/BF00262327.
9
Biliary elimination of cyclophosphamide in man.人对环磷酰胺的胆汁排泄。
Cancer Chemother Pharmacol. 1982;9(1):26-9. doi: 10.1007/BF00296757.
10
Metabolism of high doses of cyclophosphamide.高剂量环磷酰胺的代谢
Cancer Chemother Pharmacol. 1982;8(3):311-3. doi: 10.1007/BF00254056.

本文引用的文献

1
[ON THE ACTIVATION OF CYCLOPHOSPHAMIDE IN VIVO AND IN VITRO].[关于环磷酰胺在体内和体外的活化作用]
Arzneimittelforschung. 1963 Dec;13:1021-31.
2
Studies on the mechanism of action of cytoxan. Evidence of activation in vivo and in vitro.环磷酰胺作用机制的研究。体内和体外激活的证据。
Cancer Res. 1961 Jan;21:57-63.
3
Metabolism of radioactive cyclophosphamide. Animal tests and clinical studies.放射性环磷酰胺的代谢。动物试验与临床研究。
Cancer. 1967 May;20(5):896-9. doi: 10.1002/1097-0142(1967)20:5<896::aid-cncr2820200551>3.0.co;2-d.
4
Immunosuppressive therapy in steroid-resistant proliferative glomerulonephritis accompanied by the nephrotic syndrome.伴有肾病综合征的类固醇抵抗性增殖性肾小球肾炎的免疫抑制治疗
Br Med J. 1966 Oct 8;2(5518):853-60. doi: 10.1136/bmj.2.5518.853.
5
Effect of mode of administration on drug distribution in a two-compartment open system.给药方式对二室开放系统中药物分布的影响。
J Pharm Sci. 1969 Mar;58(3):327-31. doi: 10.1002/jps.2600580308.
6
Pharmacokinetic evidence for saturable renal tubular reabsorption of riboflavin.核黄素肾小管重吸收存在饱和现象的药代动力学证据。
J Pharm Sci. 1970 Jun;59(6):765-72. doi: 10.1002/jps.2600590608.
7
Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat.大鼠肝脏微粒体对环磷酰胺激活作用的酶学基础。
J Pharmacol Exp Ther. 1970 Aug;174(2):206-10.

环磷酰胺在人体中的药代动力学。

Pharmacokinetics of cyclophosphamide in man.

作者信息

Cohen J L, Jao J Y, Jusko W J

出版信息

Br J Pharmacol. 1971 Nov;43(3):677-80. doi: 10.1111/j.1476-5381.1971.tb07199.x.

DOI:10.1111/j.1476-5381.1971.tb07199.x
PMID:5157730
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1665783/
Abstract
  1. The pharmacokinetics of cyclophosphamide were investigated in cancer patients. The data can be characterized by a two-compartment open model. The half life of the elimination phase of the drug ranged between 3 and 11 hours.2. Extensive tubular reabsorption of the drug resulted in the excretion of only a small percentage of the administered dose. The mean renal clearance was 10.7 ml/minute.3. The calculated fraction of the dose of drug which was metabolized averaged 88%.
摘要

  1. 在癌症患者中研究了环磷酰胺的药代动力学。数据可用二室开放模型表征。该药物消除相的半衰期在3至11小时之间。

  2. 药物广泛的肾小管重吸收导致仅排出给药剂量的一小部分。平均肾清除率为10.7毫升/分钟。

  3. 计算得出药物代谢剂量的平均比例为88%。